Chloramphenicol Inj Rx
Generic Name and Formulations:
Chloramphenicol sodium succinate 100mg/mL; pwd for IV inj after reconstitution; sodium content 2.25 mEq/g chloramphenicol; preservative-free.
Various generic manufacturers
Indications for Chloramphenicol Inj:
Serious susceptible infections resistant to other antibiotics. Typhoid fever. Cystic fibrosis regimens.
Give by IV inj over ≥1-minute interval. 50mg/kg per day in 4 divided doses every 6 hours. Moderately resistant infections: may increase up to 100mg/kg per day, reduce dose as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Renal or hepatic impairment: adjust or reduce dose. Switch to oral form as soon as possible.
Give by IV inj over ≥1-minute interval. Premature, full-term infants <2 weeks old, or children with immature metabolic processes: 25mg/kg per day in 4 divided doses every 6 hours. Children >2 weeks old: up to 50mg/kg per day in 4 divided doses every 6 hours. Severe infections (eg, bacteremia, meningitis): up to 100mg/kg per day, reduce to 50mg/kg per day as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Switch to oral form as soon as possible.
Not for trivial infections or prophylaxis. Previous toxic reactions to chloramphenicol.
Renal or hepatic impairment. Obtain baseline CBCs then every 2 days during therapy; discontinue if blood dyscrasias, optic neuritis or peripheral neuritis develops. Avoid repeat therapy. Monitor serum levels. Premature and newborn infants. Labor & delivery. Pregnancy. Nursing mothers.
Avoid other bone marrow suppressants.
Serious/fatal blood dyscrasias, paroxysmal nocturnal hemoglobinemia, GI upset, headache, confusion, delirium, optic and peripheral neuritis, gray baby syndrome, rashes, anaphylaxis, Herxheimer reactions (w. typhoid fever).
Formerly known under the brand names Chlormycetin, Mychel S.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage